CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
CNS Pharmaceuticals (NASDAQ:CNSP) announced that its abstract has been accepted for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024), taking place November 21-24, 2024 in Houston, TX. The presentation, titled 'Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs. Lomustine After First-Line Therapy for Glioblastoma Multiforme (GBM)', will be presented by Chief Medical Officer Sandra Silberman, MD, PhD, on November 22, 2024.
CNS Pharmaceuticals (NASDAQ:CNSP) ha annunciato che il suo abstract è stato accettato per la presentazione in formato poster al 29° Congresso Annuale della Società per la Neuro-Oncologia (SNO 2024), che si terrà dal 21 al 24 novembre 2024 a Houston, TX. La presentazione, intitolata 'Aggiornamento su un Trial Potenzialmente Pivotal CNS-201: uno Studio Controllato, Randomizzato di Berubicin contro Lomustina Dopo la Terapia di Prima line dell Glioblastoma Multiforme (GBM)', sarà presentata dal Chief Medical Officer Sandra Silberman, MD, PhD, il 22 novembre 2024.
CNS Pharmaceuticals (NASDAQ:CNSP) anunció que su resumen ha sido aceptado para presentación en póster en la 29ª Reunión Anual de la Sociedad de Neuro-Oncología (SNO 2024), que se llevará a cabo del 21 al 24 de noviembre de 2024 en Houston, TX. La presentación, titulada 'Actualización sobre un posible ensayo clave CNS-201: un ensayo controlado y aleatorizado de Berubicina frente a Lomustina tras la terapia de primera línea para el Glioblastoma Multiforme (GBM)', será presentada por la Directora Médica Sandra Silberman, MD, PhD, el 22 de noviembre de 2024.
CNS Pharmaceuticals (NASDAQ:CNSP)는 그들의 초록이 제29회 신경종양학회 연례회의 (SNO 2024)에서 포스터 발표로 채택되었다고 발표했습니다. 이 회의는 2024년 11월 21일부터 24일까지 텍사스 주 휴스턴에서 열립니다. 발표 제목은 '잠재적으로 중요한 시험 CNS-201 업데이트: 첫 번째 치료 후 베루비신과 로무스틴의 무작위 대조 시험'이며, 2024년 11월 22일 최고 의료 책임자인 샌드라 실버만(Sandra Silberman), MD, PhD가 발표할 예정입니다.
CNS Pharmaceuticals (NASDAQ:CNSP) a annoncé que son résumé a été accepté pour une présentation sous forme de poster lors de la 29e Réunion Annuelle de la Société de Neuro-Oncologie (SNO 2024), qui se déroulera du 21 au 24 novembre 2024 à Houston, TX. La présentation, intitulée 'Mise à jour sur un essai potentiellement décisif CNS-201 : un essai contrôlé randomisé de Berubicin contre Lomustine après un traitement de première ligne pour le glioblastome multiforme (GBM)', sera présentée par la Directrice Médicale Sandra Silberman, MD, PhD, le 22 novembre 2024.
CNS Pharmaceuticals (NASDAQ:CNSP) hat bekannt gegeben, dass sein Abstract für eine Posterpräsentation auf dem 29. Jahresmeeting der Society for Neuro-Oncology (SNO 2024) akzeptiert wurde, das vom 21. bis 24. November 2024 in Houston, TX, stattfindet. Die Präsentation mit dem Titel 'Update zu einer potenziell entscheidenden Studie CNS-201: Eine randomisierte, kontrollierte Studie von Berubicin gegen Lomustin nach der Erstlinientherapie für Glioblastoma Multiforme (GBM)' wird von Chief Medical Officer Sandra Silberman, MD, PhD, am 22. November 2024 präsentiert.
- None.
- None.
HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX.
Details of the presentation are as follows:
Title:Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs. Lomustine After First-Line Therapy for Glioblastoma Multiforme (GBM)
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Program Code: CTNI-68
Category: Poster and Networking Session
Date and Time: Friday , November 22, 2024 from 7:30 - 9:30 PM CT
Location: Hall B3, George R Brown Convention Center
For more information about SNO 2024, please visit the conference website.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When will CNS Pharmaceuticals (CNSP) present their Berubicin trial update at SNO 2024?
What is the topic of CNS Pharmaceuticals' (CNSP) presentation at SNO 2024?
Who will present CNS Pharmaceuticals' (CNSP) poster at SNO 2024?
